Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Farmers Insurance
Mallinckrodt
Harvard Business School
Merck
Teva
Baxter
Covington
Colorcon
Dow

Generated: August 18, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title:Methods of providing therapeutic effects using cyclosporin components
Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.
Inventor(s): Acheampong; Andrew (Irvine, CA), Tang-Liu; Diane D. (Las Vegas, NV), Chang; James N. (Newport Beach, CA), Power; David F. (Hubert, NC)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:13/967,163
Patent Claims: 1. A topical ophthalmic emulsion for treating an eye of a human comprising cyclosporin A in an amount of about 0.05% by weight, polysorbate 80, acrylate/C10-30 alkyl acrylate cross-polymer, water, and castor oil in an amount of about 1.25% by weight; wherein cyclosporin A is the only peptide present in the topical ophthalmic emulsion.

2. The topical ophthalmic emulsion of claim 1, wherein the topical ophthalmic emulsion further comprises a tonicity agent or a demulcent component.

3. The topical ophthalmic emulsion of claim 2, wherein the tonicity agent or the demulcent component is glycerine.

4. The topical ophthalmic emulsion of claim 1, wherein the topical ophthalmic emulsion further comprises a buffer.

5. The topical ophthalmic emulsion of claim 4, wherein the buffer is sodium hydroxide.

6. The topical ophthalmic emulsion of claim 1, wherein the topical ophthalmic emulsion further comprises glycerine and a buffer.

7. The topical ophthalmic emulsion of claim 1, wherein the topical ophthalmic emulsion comprises polysorbate 80 in an amount of about 1.0% by weight.

8. The topical ophthalmic emulsion of claim 1, wherein the topical ophthalmic emulsion comprises acrylate/C10-30 alkyl acrylate cross-polymer in an amount of about 0.05% by weight.

9. The topical ophthalmic emulsion of claim 1, wherein the topical ophthalmic emulsion further comprises glycerine in an amount of about 2.2% by weight, water, and a buffer.

10. The topical ophthalmic emulsion of claim 9, wherein the buffer is sodium hydroxide.

11. The topical ophthalmic emulsion of claim 1, wherein, when the topical ophthalmic emulsion is administered to an eye of a human, the blood of the human has substantially no detectable concentration of cyclosporin A.

12. The topical ophthalmic emulsion of claim 6, wherein the topical ophthalmic emulsion has a pH in the range of about 7.2 to about 7.6.

13. A topical ophthalmic emulsion for treating an eye of a human, wherein the topical ophthalmic emulsion comprises: cyclosporin A in an amount of about 0.05% by weight; castor oil in an amount of about 1.25% by weight; polysorbate 80 in an amount of about 1.0% by weight; acrylate/C10-30 alkyl acrylate cross-polymer in an amount of about 0.05% by weight; a tonicity component or a demulcent component in an amount of about 2.2% by weight; a buffer; and water; wherein the topical ophthalmic emulsion has a pH in the range of about 7.2 to about 7.6 and wherein cyclosporin A is the only peptide present in the topical ophthalmic emulsion.

14. The topical ophthalmic emulsion of claim 13, wherein the buffer is sodium hydroxide.

15. The topical ophthalmic emulsion of claim 13, wherein the tonicity component or the demulcent component is glycerine.

16. The topical ophthalmic emulsion of claim 13, wherein, when the topical ophthalmic emulsion is administered to an eye of a human, the blood of the human has substantially no detectable concentration of the cyclosporin A.

17. The topical ophthalmic emulsion of claim 13, wherein the topical ophthalmic emulsion is effective in treating keratoconjunctivitis sicca.

18. A topical ophthalmic emulsion for treating an eye of a human, the topical ophthalmic emulsion comprising: cyclosporin A in an amount of about 0.05% by weight; castor oil in an amount of about 1.25% by weight; polysorbate 80 in an amount of about 1.0% by weight; acrylate/C10-30 alkyl acrylate cross-polymer in an amount of about 0.05% by weight; glycerine in an amount of about 2.2% by weight; sodium hydroxide; and water; wherein cyclosporin A is the only peptide present in the topical ophthalmic emulsion.

19. The topical ophthalmic emulsion of claim 18, wherein the topical ophthalmic emulsion has a pH in the range of about 7.2 to about 7.6.

20. The topical ophthalmic emulsion of claim 1, wherein the topical ophthalmic emulsion is therapeutically effective in treating dry eye.

21. The topical ophthalmic emulsion of claim 1, wherein the topical ophthalmic emulsion is therapeutically effective in treating keratoconjunctivitis sicca.

22. The topical ophthalmic emulsion of claim 1, wherein the topical ophthalmic emulsion is therapeutically effective in increasing tear production.

23. The topical ophthalmic emulsion of claim 13, wherein the topical ophthalmic emulsion is therapeutically effective in treating dry eye.

24. The topical ophthalmic emulsion of claim 13, wherein the topical ophthalmic emulsion is therapeutically effective in increasing tear production.

25. The topical ophthalmic emulsion of claim 18, wherein the topical ophthalmic emulsion is therapeutically effective in treating dry eye.

26. The topical ophthalmic emulsion of claim 18, wherein the topical ophthalmic emulsion is therapeutically effective in treating keratoconjunctivitis sicca.

27. The topical ophthalmic emulsion of claim 18, wherein the topical ophthalmic emulsion is therapeutically effective in increasing tear production.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
Accenture
Citi
Chubb
Medtronic
Covington
Cipla
Argus Health
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot